Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May-Jun;28(3):399-405.
doi: 10.1016/j.jdiacomp.2014.01.009. Epub 2014 Jan 21.

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials

Vivian A Fonseca  1 , J Hans Devries  2 , Robert R Henry  3 , Morten Donsmark  4 , Henrik F Thomsen  5 , Jorge Plutzky  6
Affiliations

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials

Vivian A Fonseca et al. J Diabetes Complications. 2014 May-Jun.

Abstract

Aims: To quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions.

Methods: A patient-level pooled analysis of six phase 3, randomized trials was conducted.

Results: The analysis included 2792 randomized patients. In the intention-to-treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2 mg (2.7 [0.8] mmHg) and 1.8 mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8 mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson's correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8 mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1 bpm increase with placebo (P<0.0001 for each dose versus placebo).

Conclusions: Liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.

Trial registration: ClinicalTrials.gov NCT00294723 NCT00318422 NCT00318461 NCT00331851 NCT00333151 NCT00518882.

Keywords: Blood pressure; Hypertension; Liraglutide; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: V.F. has received advisory board honoraria and speakers’ bureau honoraria from Novo Nordisk, and his institution has received research funding from Novo Nordisk; V.F. is currently Editor-in-Chief of this journal. J.H.D. or his institution has received advisory board honoraria and speakers’ bureau honoraria from Novo Nordisk, and his institution has received research funding from Novo Nordisk. R.H.’s institution has received research funding from Novo Nordisk. J.P. has received consultancy fees from Novo Nordisk. M.D. and H.T. are currently employed by and own shares in Novo Nordisk A/S. These analyses were sponsored by Novo Nordisk A/S, Copenhagen, Denmark. All authors discussed the data, edited the manuscript for important intellectual content, and approved the version for publication. H.T carried out the statistical analyses.

Figures

Fig. 1
Fig. 1. Change in systolic blood pressure (SBP) with liraglutide versus placebo and active comparators
Diamonds indicate liraglutide–placebo or liraglutide–active comparator estimated treatment differences in change in SBP from baseline (analysis of covariance models) for pooled data from LEAD-1–6. The width of the horizontal lines indicates 95% confidence intervals for each estimated treatment difference. LS, least squares; SBP, systolic blood pressure.
Fig. 2
Fig. 2. Change in systolic blood pressure (SBP) over time
Data are last observation carried forward for the intention-to-treat population, and expressed as least squares means ± 95% confidence interval.
See this image and copyright information in PMC

References

    1. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ. 2000;321:412–419. - PMC - PubMed
    1. American Diabetes Association. Standards of medical care in diabetes – 2013. Diabetes Care. 2013;36(Suppl 1):S11–S66. - PMC - PubMed
    1. Amylin Pharmaceuticals, LLC. [accessed 8 Aug 2013];Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. 2012 Available at: http://clinicaltrials.gov/show/NCT01144338.
    1. Arauz-Pacheco C, Parrott MA, Raskin P American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(Suppl 1):S80–S82. - PubMed
    1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340–2350. - PubMed

Publication types

MeSH terms

Associated data